Illumina, Inc. (ILMN)
| Chiusura precedente | 369,43 |
| Aperto | 368,15 |
| Denaro | 368,09 x 800 |
| Lettera | 368,84 x 1200 |
| Min-Max giorno | 366,40 - 372,58 |
| Intervallo di 52 settimane | 336,00 - 555,77 |
| Volume | |
| Media Volume | 877.242 |
| Capitalizzazione | 57,829B |
| Beta (5 anni mensile) | 0,89 |
| Rapporto PE (ttm) | 60,56 |
| EPS (ttm) | 6,11 |
| Prossima data utili | 09 feb 2022 - 14 feb 2022 |
| Rendimento e dividendo (forward) | N/D (N/D) |
| Data ex dividendo | N/D |
| Stima target 1A | 437,13 |
- GlobeNewswire
Dante Labs Announces Appointment of Global Legal Expert Rachel Haverfield as General Counsel to its Expanding Leadership Team
CAMBRIDGE, United Kingdom, Sept. 16, 2021 (GLOBE NEWSWIRE) -- Dante Labs, a global leader in genomics and precision medicine, today announced the appointment of Rachel Haverfield to the company’s leadership as General Counsel to drive the growth and scale of the business and opportunity. “We are so pleased to have Rachel joining Dante’s growing leadership of top talent in the industry,” said Andrea Riposati, CEO of Dante Labs. “Rachel’s global, legal commercial, regulatory and compliance experti
- GlobeNewswire
Dante Labs Announces Expansion of its Finance Team with the Appointment of Andre Nel as Chief Financial Officer, Dalila Rahmani as Chief Accounting Officer, Laura D’Angelo as VP Investor Relations and Omar Elbakshish as Senior Director
CAMBRIDGE, United Kingdom, Sept. 14, 2021 (GLOBE NEWSWIRE) -- Dante Labs, a global leader in genomics and precision medicine, today announced the appointments of Andre Nel, Dalila Rahmani, Laura D’Angelo and Omar Elbakshish to the company’s management team, expanding its global leadership to help scale the growing business. “We are thrilled to welcome Andre, Dalila, Laura and Omar to the expanding leadership team here at Dante,” said Andrea Riposati, CEO of Dante Labs. “As we work to deliver a m
- GlobeNewswire
INVESTOR ALERT. An Investor Investigation Is Underway Regarding Illumina’s Closing of Its GRAIL Acquisition Without Obtaining EU Approval
SAN DIEGO, Aug. 23, 2021 (GLOBE NEWSWIRE) -- To: All persons or entities who hold common stock of Illumina, Inc. (“Illumina” or the “Company”) (NASDAQ: ILMN). You are hereby notified that Bottini & Bottini, Inc. is investigating potential claims on behalf of Illumina shareholders relating to Illumina’s acquisition of GRAIL, Inc. (“the Acquisition”) without approval by the European Commission. On August 18, 2021, Illumina announced that it had closed its acquisition of GRAIL, a cancer diagnostic
